RU2007116039A - Сульфонилзамещенные бициклические соединеия в качестве модуляторов ppar - Google Patents

Сульфонилзамещенные бициклические соединеия в качестве модуляторов ppar Download PDF

Info

Publication number
RU2007116039A
RU2007116039A RU2007116039/04A RU2007116039A RU2007116039A RU 2007116039 A RU2007116039 A RU 2007116039A RU 2007116039/04 A RU2007116039/04 A RU 2007116039/04A RU 2007116039 A RU2007116039 A RU 2007116039A RU 2007116039 A RU2007116039 A RU 2007116039A
Authority
RU
Russia
Prior art keywords
optionally substituted
group
hydrogen
independently selected
lower alkyl
Prior art date
Application number
RU2007116039/04A
Other languages
English (en)
Other versions
RU2384576C2 (ru
Inventor
Стюарт А. НОБЛ (US)
Стюарт А. НОБЛ
Гай ОШИРО (US)
Гай ОШИРО
Джеймс В. МАЛЕЧА (US)
Джеймс В. МАЛЕЧА
Кунсян ЖАО (US)
Кунсян ЖАО
Кармен К. М. РОБИНСОН (US)
Кармен К. М. РОБИНСОН
Серджио Дж. ДЮРОН (US)
Серджио Дж. ДЮРОН
Майкл СЕРТИЧ (US)
Майкл СЕРТИЧ
Эндрю ЛИНДСТРОМ (US)
Эндрю ЛИНДСТРОМ
Эндрю ШИАУ (US)
Эндрю ШИАУ
Кристофер Д. БЭЙН (US)
Кристофер Д. БЭЙН
Стивен П. ГОВЕК (US)
Стивен П. Говек
Мехмет КАРАМАН (US)
Мехмет Караман
Болян ЛУ (US)
Болян ЛУ
Original Assignee
Калипсис
Калипсис, Инк
Инк (Us)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Калипсис, Калипсис, Инк, Инк (Us) filed Critical Калипсис
Publication of RU2007116039A publication Critical patent/RU2007116039A/ru
Application granted granted Critical
Publication of RU2384576C2 publication Critical patent/RU2384576C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1. Соединение, имеющее структурную формулу, выбранную из группы, состоящей из формулы II, формулы III и формулы IVиили его соль, сложный эфир или пролекарство,где Gвыбран из группы, включающей -(CRR)-, -Z(CRR)-, -(CRR)Z-, -(CRR)Z(CRR)-;Z является О, S или NR;n равно О, 1 или 2;r и s независимо выбраны из 0 и 1;Rи Rнезависимо выбраны из группы, включающей водород, гало, необязательно замещенный низший алкил, необязательно замещенный низший гетероалкил, необязательно замещенный низший алкокси и низший пергалоалкил, или вместе могут образовывать необязательно замещенный циклоалкил;X, X, и Хнезависимо выбраны из группы, включающей водород, необязательно замещенный низший алкил, необязательно замещенный циклоалкил, галоген, пергалоалкил, гидрокси, необязательно замещенный низший алкокси, нитро, циано и NH;Gвыбран из группы, включающей насыщенный или ненасыщенный циклоалкил или гетероциклоалкильный линкер, необязательно замещенный Хи Х;Хи Xнезависимо выбраны из группы, включающей водород, необязательно замещенный низший алкил, галоген, низший пергалоалкил, гидрокси, необязательно замещенный низший алкокси, нитро, циано, NHи COR, или Хи Хвместе могут образовывать углеродный цикл;R выбран из группы, состоящей из необязательно замещенного низшего алкила и водорода;Gвыбран из группы, включающей связь, двойную связь, -(CRR)-, карбонил и -(CRR)CR=CR-;m равно 0, 1 или 2;Rи Rнезависимо выбраны из группы, включающей водород, необязательно замещенный низший алкил, необязательно замещенный низший алкокси, необязательно замещенный арил, низший пергалоалкил, циано и нитро;Gвыбран из группы, включающей водород, необязательно замещенный арил, необязательно замещенный гетероарил

Claims (9)

1. Соединение, имеющее структурную формулу, выбранную из группы, состоящей из формулы II, формулы III и формулы IV
Figure 00000001
Figure 00000002
и
Figure 00000003
или его соль, сложный эфир или пролекарство,
где G1 выбран из группы, включающей -(CR1R2)n-, -Z(CR1R2)n-, -(CR1R2)nZ-, -(CR1R2)rZ(CR1R2)s-;
Z является О, S или NR;
n равно О, 1 или 2;
r и s независимо выбраны из 0 и 1;
R1 и R2 независимо выбраны из группы, включающей водород, гало, необязательно замещенный низший алкил, необязательно замещенный низший гетероалкил, необязательно замещенный низший алкокси и низший пергалоалкил, или вместе могут образовывать необязательно замещенный циклоалкил;
X1, X2, и Х3 независимо выбраны из группы, включающей водород, необязательно замещенный низший алкил, необязательно замещенный циклоалкил, галоген, пергалоалкил, гидрокси, необязательно замещенный низший алкокси, нитро, циано и NH2;
G2 выбран из группы, включающей насыщенный или ненасыщенный циклоалкил или гетероциклоалкильный линкер, необязательно замещенный Х4 и Х5;
Х4 и X5 независимо выбраны из группы, включающей водород, необязательно замещенный низший алкил, галоген, низший пергалоалкил, гидрокси, необязательно замещенный низший алкокси, нитро, циано, NH2 и CO2R, или Х4 и Х5 вместе могут образовывать углеродный цикл;
R выбран из группы, состоящей из необязательно замещенного низшего алкила и водорода;
G3 выбран из группы, включающей связь, двойную связь, -(CR3R4)m-, карбонил и -(CR3R4)mCR3=CR4-;
m равно 0, 1 или 2;
R3 и R4 независимо выбраны из группы, включающей водород, необязательно замещенный низший алкил, необязательно замещенный низший алкокси, необязательно замещенный арил, низший пергалоалкил, циано и нитро;
G4 выбран из группы, включающей водород, необязательно замещенный арил, необязательно замещенный гетероарил, необязательно замещенный циклоалкил, необязательно замещенный циклогетероалкил, необязательно замещенный циклогетероарил, необязательно замещенный циклоалкенил и -N=(CR5R6); и
R5 и R6 независимо выбраны из группы, включающей водород, необязательно замещенный алкил, необязательно замещенный арил, необязательно замещенный гетероарил, необязательно замещенный циклоалкил, необязательно замещенный циклоалкенил и необязательно замещенный циклогетероалкил.
2. Соединение по п.1, имеющее структурную формулу, выбранную из группы, состоящей из
Figure 00000004
и
Figure 00000005
где G1 выбран из группы, включающей -(CR1R2)n- и -(CR1R2)nO-;
Z является О, S или NR;
n равно 0 или 1;
G2 имеет структуру
Figure 00000006
X1, X2, и Х3 - водород;
Х4 и X5 независимо выбраны из группы, включающей водород и низший алкил;
р равно 1, 2 или 3;
W выбран из группы, состоящей из -CX4Х5- и N-X7;
Х6 выбран из группы, включающей водород, алкил, гидрокси, алкокси, циано, галоген, низший пергалоалкил и NH2, или же не является ничем при образовании двойной связи с атомом соседнего кольца;
X7 выбран из группы, включающей водород, алкил, гидрокси и низший пергалоалкил, или же не является ничем при образовании двойной связи с Y2;
G3 выбран из группы, включающей связь и -(CR3R4)m-; и
R3 и R4 независимо выбраны из группы, включающей водород и низший алкил.
3. Соединение по п.2, отличающееся тем, что
р равно 2;
W является CX4Х5;
Х4 и X5 независимо выбраны из группы, включающей водород и метил;
Y1 является N;
G1 является -(CR1R2)n-;
R1 и R2 являются водородом и
G4 является арилом или гетероарилом, любой из которых может быть замещен галогеном, низшим алкилом, низшим пергалоалкилом, низшим пергалоалкокси, моно- или дигалоалкокси.
4. Соединение по п.3, отличающееся тем, что
G3 выбран из группы, включающей связь и -СН2-;
G4 является фенилом или пиридинилом, любой из которых единожды или дважды замещен галогеном, низшим алкилом, низшим пергалоалкилом, низшим пергалоалкокси, моно- или дигалоалкокси; и
Y2 является N.
5. Соединение по п.4, отличающееся тем, что Х4 и X5 являются метилом и присоединены к пиперазиновому кольцу в положениях 2 и 6; и
G4 является фенилом, паразамещенным заместителем, выбранным из группы, включающей трифторметил и трифторметокси.
6. Соединение, выбранное из группы, состоящей из соединений, описанных в примерах 1-107 и 110-117.
7. Соединение, выбранное из группы, состоящей из (S)-4-[цис-2,6-диметил-4-(4-трифторметокси-фенил)-пиперазин-1-сульфонил]-индан-2-уксусной кислоты и (S)-4-[цис-2,6-диметил-4-(4-трифторметокси-бензил)-пиперазин-1-сульфонил]-индан-2-уксусной кислоты, или его соль.
8. Соль, выбранная из группы, состоящей из тозилата (S)-4-[цис-2,6-диметил-4-(4-трифторметокси-фенил)-пиперазин-1-сульфонил]-индан-2-уксусной кислоты и тозилата (S)-4-[цис-2,6-диметил-4-(4-трифторметокси-бензил)-пиперазин-1-сульфонил]-индан-2-уксусной кислоты.
9. Фармацевтическая композиция, включающая соединение по любому из пп.1-8 и фармацевтически приемлемый носитель.
RU2007116039/04A 2004-10-29 2005-10-25 Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar RU2384576C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62325204P 2004-10-29 2004-10-29
US60/623,252 2004-10-29
US67981305P 2005-05-11 2005-05-11
US60/679,813 2005-05-11

Publications (2)

Publication Number Publication Date
RU2007116039A true RU2007116039A (ru) 2008-12-10
RU2384576C2 RU2384576C2 (ru) 2010-03-20

Family

ID=36071948

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007116039/04A RU2384576C2 (ru) 2004-10-29 2005-10-25 Сульфонил-замещенные бициклические соединения в качестве модуляторов ppar

Country Status (16)

Country Link
US (3) US7494999B2 (ru)
EP (1) EP1805158B1 (ru)
JP (1) JP5138377B2 (ru)
KR (1) KR101404930B1 (ru)
AR (1) AR052319A1 (ru)
AU (1) AU2005307006B2 (ru)
BR (1) BRPI0516435B1 (ru)
CA (1) CA2585172C (ru)
DK (1) DK1805158T3 (ru)
ES (1) ES2682282T3 (ru)
HU (1) HUE039584T2 (ru)
IL (1) IL182427A (ru)
MX (1) MX2007005205A (ru)
NZ (1) NZ589748A (ru)
RU (1) RU2384576C2 (ru)
WO (1) WO2006055187A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
WO2004092117A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
CA2521135A1 (en) * 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
CA2585172C (en) 2004-10-29 2014-08-12 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
US20070190079A1 (en) * 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
EP1915371A4 (en) * 2005-08-19 2010-09-15 Elan Pharm Inc BREAKDOWN N-BICYCLIC SULPHONAMIDE INHIBITORS OF GAMMA LASE CRETEASE
US8080579B2 (en) * 2005-10-03 2011-12-20 The Regents Of The University Of Michigan Compositions and methods for treatment of inflammatory bowel disease
WO2007047432A1 (en) * 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
HUE040020T2 (hu) * 2005-10-25 2019-02-28 Kalypsys Inc PPAR modulátorok sói és eljárások metabolikus betegségek kezelésére
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
JP2009526023A (ja) 2006-02-10 2009-07-16 ノイロサーチ アクティーゼルスカブ ３，９−ジアザビシクロ［３．３．１］ノナン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのその使用
AU2007213669A1 (en) 2006-02-10 2007-08-16 Neurosearch A/S 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7687523B2 (en) 2006-02-10 2010-03-30 Neurosearch A/S 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
EP1988077A4 (en) * 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
US20070249519A1 (en) * 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
TW200745059A (en) * 2006-05-16 2007-12-16 Kalypsys Inc Sulfonyl-substituted bicyclic compounds as modulators of PPAR
WO2008043024A2 (en) * 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
WO2008091863A1 (en) * 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
EP2139845A1 (en) * 2007-02-26 2010-01-06 Teva Pharmaceutical Industries Ltd. Intermediates and processes for the synthesis of ramelteon
CN101663292A (zh) 2007-04-23 2010-03-03 詹森药业有限公司 作为快速解离的多巴胺2受体拮抗剂的4-烷氧基哒嗪衍生物
CA2682671C (en) 2007-04-23 2015-11-17 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
EP2098519A1 (en) 2007-05-31 2009-09-09 Teva Pharmaceutical Industries Ltd. Process for the synthesis of ramelteon and its intermediates
CN102159554B (zh) 2008-07-03 2014-09-24 詹森药业有限公司 作为5-ht6受体拮抗剂的取代的6-(1-哌嗪基)-哒嗪
LT2307374T (lt) 2008-07-31 2017-04-25 Janssen Pharmaceutica Nv Piperazin-1-il-trifluormetil-pakeistieji piridinai kaip greitai disocijuojantys dopamino 2 receptoriaus antagonistai
ES2390589T3 (es) * 2008-10-09 2012-11-14 Bayer Cropscience Ag Procedimiento para la preparación de piridinas sustituidas con trihalometoxi funcionalizadas
WO2010121212A2 (en) * 2009-04-17 2010-10-21 H. Lee Moffit Cancer Center And Research Institute, Inc. Indoline scaffold shp-2 inhibitors and method of treating cancer
CA2809958A1 (en) 2010-08-31 2012-03-08 Snu R & Db Foundation Use of the fetal reprogramming of a ppar ? agonist
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
CA3076907A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. Niraparib formulations
HRP20220331T1 (hr) 2018-03-08 2022-05-13 Incyte Corporation Spojevi aminopirazin diola kao inhibitori pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
CN113880755B (zh) * 2021-08-27 2024-06-18 成都药明康德新药开发有限公司 2-溴-5-(三氟甲氧基)吡啶的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929803A (en) * 1974-05-28 1975-12-30 Pfizer Aryl carboxylic acids
US4237130A (en) 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
ATE30722T1 (de) 1982-10-22 1987-11-15 Ciba Geigy Ag Neue benzodioxolderivate, verfahren zu deren herstellung und entsprechende pharmazeutische zusammensetzungen.
EP0158596A3 (de) 1984-04-06 1986-08-13 Ciba-Geigy Ag Neue substituierte Benzodioxolderivate, Verfahren zu deren Herstellung und entsprechende pharmazeutische Zusammensetzungen
JPS6163671A (ja) 1984-09-05 1986-04-01 Shionogi & Co Ltd ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
NZ501619A (en) 1997-06-17 2002-02-01 Schering Corp Tricyclic sulfonamide inhibitors of farnesyl-protein transferase
ATE346050T1 (de) 1998-01-27 2006-12-15 Aventis Pharma Inc Substituierte oxoazaheterocyclyl faktor xa hemmer
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
EP1107758A2 (en) 1998-08-28 2001-06-20 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
ES2300151T3 (es) 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
US6465468B1 (en) 1999-03-22 2002-10-15 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
CN1215059C (zh) 1999-12-03 2005-08-17 京都药品工业株式会社 新的杂环化合物及其盐和它们的医药用途
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
GB0007907D0 (en) 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
JP2004513090A (ja) * 2000-09-27 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
EP2292593A3 (en) 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors
CA2433090A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
US7144883B2 (en) 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7157452B2 (en) * 2001-12-31 2007-01-02 Mgi Gp, Inc. Substituted 4,9-dihydrocyclopenta{imn}phenanthridine-5-ones derivatives thereof and their uses
WO2003082288A1 (en) 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
EP1511488B1 (en) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
US7253189B2 (en) * 2002-11-25 2007-08-07 Schering Corporation Cannabinoid receptor ligands
DE10300099A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Indol-Phenylsulfonamid-Derivate
WO2004073606A2 (en) 2003-02-14 2004-09-02 Eli Lilly And Company Sulfonamide derivatives as ppar modulators
WO2004092117A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
CA2521135A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders
ATE339205T1 (de) 2003-04-17 2006-10-15 Kalypsys Inc (3-ä3-'(2,4-bis-trifluormethyl-benzyl)-(5-ethyl pyrimidin-2-yl)-amino)-propoxyü-phenyl)- essigsäure und verwandte verbindungen als modulatoren von ppars und verfahren zur behandlung von stoffwechselstörungen
ATE556056T1 (de) 2003-07-29 2012-05-15 Xenon Pharmaceuticals Inc Pyridylderivate und deren verwendung als therapeutische mittel
JP4782008B2 (ja) 2003-07-30 2011-09-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリジル誘導体および治療剤としてのその用途
ATE532772T1 (de) 2003-07-30 2011-11-15 Xenon Pharmaceuticals Inc Piperazinderivate und deren verwendung als therapeutische mittel
KR20060037410A (ko) 2003-07-30 2006-05-03 제논 파마슈티칼스 인크. 피리다진 유도체 및 그의 치료제로서의 용도
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
EP1776106B1 (en) * 2004-06-22 2013-08-07 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
CN1997371A (zh) 2004-07-06 2007-07-11 泽农医药公司 烟酰胺衍生物及其作为治疗剂的用途
US20080167321A1 (en) 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515488A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados de heterocìclicos e seu uso como agentes terapêuticos
CA2580787A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799668A1 (en) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-coa desaturase
AR051294A1 (es) 2004-09-20 2007-01-03 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CA2585172C (en) 2004-10-29 2014-08-12 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar
US20070190079A1 (en) 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
US20090143396A1 (en) 2005-10-12 2009-06-04 Malecha James W Sulfonyl-Substituted Aryl Compounds as Modulators of Peroxisome Proliferator Activated Receptors
WO2007047432A1 (en) 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
HUE040020T2 (hu) * 2005-10-25 2019-02-28 Kalypsys Inc PPAR modulátorok sói és eljárások metabolikus betegségek kezelésére
EP1996198A1 (en) 2006-03-17 2008-12-03 Kalypsys, Inc. Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
US20070249519A1 (en) 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
TW200745059A (en) * 2006-05-16 2007-12-16 Kalypsys Inc Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20080004281A1 (en) 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
US20080287477A1 (en) 2006-10-11 2008-11-20 Kalypsys, Inc. Novel Compounds as Modulators of Ppar
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
IL182427A (en) 2016-02-29
US20090029971A1 (en) 2009-01-29
CA2585172A1 (en) 2006-05-26
AU2005307006B2 (en) 2012-05-03
IL182427A0 (en) 2007-07-24
MX2007005205A (es) 2007-05-11
DK1805158T3 (en) 2018-08-06
JP2008518912A (ja) 2008-06-05
US7494999B2 (en) 2009-02-24
EP1805158A1 (en) 2007-07-11
BRPI0516435A (pt) 2008-09-02
CA2585172C (en) 2014-08-12
RU2384576C2 (ru) 2010-03-20
AU2005307006A1 (en) 2006-05-26
KR20070089786A (ko) 2007-09-03
US7834004B2 (en) 2010-11-16
US7915253B2 (en) 2011-03-29
NZ589748A (en) 2012-09-28
KR101404930B1 (ko) 2014-06-09
US20060167012A1 (en) 2006-07-27
BRPI0516435B1 (pt) 2021-09-21
US20090264417A1 (en) 2009-10-22
HUE039584T2 (hu) 2019-01-28
WO2006055187A1 (en) 2006-05-26
AR052319A1 (es) 2007-03-14
ES2682282T3 (es) 2018-09-19
EP1805158B1 (en) 2018-06-27
JP5138377B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
RU2007116039A (ru) Сульфонилзамещенные бициклические соединеия в качестве модуляторов ppar
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
AP1635A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease.
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
EP1829858A3 (en) Dibenzylamine compounds and pharmaceutical use thereof
TW200640862A (en) Pyridyl acetic acid compounds
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists
AR047339A1 (es) Derivados de difenilazetidona.proceso de obtencion.
TW200407309A (en) 1,2-Azole derivatives
MY144960A (en) Morpholine type cinnamide compound
EP1724262A4 (en) 1- (2H) -ISOCHINOLONDERIVAT
JP2010535722A5 (ru)
SG153811A1 (en) Quinazolinone derivatives useful as vanilloid antagonists
WO2008108380A3 (en) Pyrrole compounds
EA200300718A1 (ru) Производные 3-индолина, которые могут применяться при лечении психиатрических и неврологических расстройств
EA200800502A1 (ru) Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
BRPI0619894B8 (pt) composto de amina e composição farmacêutica
WO2008136444A1 (ja) 縮合複素環誘導体
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
ATE429429T1 (de) Pharmazeutisches verfahren und damit hergestellte verbindungen
TW200604161A (en) Chemical process
MY138466A (en) Aminoalkoxyndoles as 5-ht6-receptor ligands for the treatment of cns-disorders
MX2011007272A (es) Piperidinas de aroilamino y heteroaroilamino sustituidas como inhibidores de glyt-1.

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20151026